-
「同位素标记抑制剂」CAS:1423119-98-5|Dabrafenib-d9
作者：德尔塔生物 日期：2025-06-13
生物活性：Dabrafenib-d9 is the deuterium labeled Dabrafenib. Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Dabrafenib-d9 相关抗体:BRAF AntibodyPhospho-BRAF (Thr401) AntibodyA-RAF AntibodyB-Raf AntibodyRaf1 AntibodyRKIP Antibody (YA1869)A RAF Antibody (YA2673)分子量：528.62Formula：C23H11D9F3N5O2S2CAS 号：1423119-98-5非标记 CAS：1195765-45-7中文名称：达拉非尼 d9运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (535 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920. [Content Brief][3]. Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruptio
-
「同位素标记抑制剂」CAS:1217860-13-3|Diltiazem-(acetoxy-d3) (hydrochloride)
作者：德尔塔生物 日期：2025-06-13
生物活性：Diltiazem-(acetoxy-d3) (hydrochloride) is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist)[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Diltiazem-(acetoxy-d3) (hydrochloride) 相关抗体:Annexin VI AntibodyCalbindin AntibodyCalreticulin AntibodyCardiac Troponin I/TNNC1 AntibodySCGN Antibody (YA1167)RAMP1 Antibody (YA1818)Annexin V Antibody (YA1829)Striatin 4 Antibody (YA2088)Fibulin 5 Antibody (YA2448)RASGRP1 Antibody (YA2546)Fibulin 1 Antibody (YA2831)EFEMP1 Antibody (YA2883)CRCP Antibody (YA3350)Annexin VII Antibody (YA1138)Parvalbumin Antibody (YA1249)Annexin IV Antibody (YA1921)SERCA2 ATPase Antibody (YA1931)Stromal Interaction Molecule 1 Antibody (YA2092)SERCA1 ATPase Antibody (YA2157)TrpV5 Antibody (YA2284)NCX1 Antibody (YA2331)Scramblase 1 Antibody (YA2419)CAB39 Antibody (YA2761)CUG BP1 Antibody (YA2806)C10orf63 Antibody (YA2894)ITPK1 Antibody (YA3125)ORAI3 Antibody (YA3128)ORAI1 Antibody (YA3157)CREB Regulated Transcription Coactivator 2 Antibody (YA3279)分子量：454.00Formula：C22H24D3ClN2O4SCAS 号：1217860-13-3非标记 CAS：33286-22-5中文名称：盐酸地尔硫卓 d3 (盐酸盐)运输条件：Room temperat
-
「同位素标记抑制剂」CAS:115473-56-8|L-Glutamic acid-13C2
作者：德尔塔生物 日期：2025-06-13
生物活性：L-Glutamic acid-13C2 is the 13C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.L-Glutamic acid-13C2 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)ERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C AntibodyMETTL3 AntibodyPSD95 Antibodyc-Myc AntibodyCyclin E1 AntibodyTSG101 AntibodyAIF Antibody (YA636)ALIX AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)CNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 Antibody分子量：149.11Formula：C313C2H9NO4CAS 号：115473-56-8非标记 CAS：56-86-0中文名称：L-谷氨酸-13C2运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in
-
「同位素标记抑制剂」CAS:1216757-55-9|Rasagiline-13C3 mesylate racemic
作者：德尔塔生物 日期：2025-06-13
生物活性：Rasagiline-13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.体外研究(In Vitro)：Rasagiline mesylate racemic is the racemic mixture of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Rasagiline-13C3 mesylate racemic 相关抗体:Monoamine Oxidase A Antibody (YA2036)Monoamine Oxidase B Antibody (YA2039)Clinical TrialNCT NumberSponsorConditionStart DatePhaseNCT01187888Prof. Dr. Stefan Lorenzl|Teva Branded Pharmaceutical Products R&D, Inc.|Ludwig-Maximilians - University of MunichProgressive Supranuclear PalsyJanuary 2010Phase 3NCT00203060Teva Neuroscience, Inc.|Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseJuly 1997Phase 3NCT01532141Bial - Portela C S.A.Parkinson DiseaseNovember 2009Phase 1 NCT02789020University of Florida|National Institute of Neurological Disorders and Stroke (NINDS)Parkinson´s DiseaseDecember 2016Phase 2NCT00977665Teva Branded Pharmaceutical Products R&D, Inc.|H. Lundbeck A+SMultiple System AtrophyDecember 2009Phase 2NCT01652313H. Lundbeck A+SParkinson´s DiseaseMay
-
「同位素标记抑制剂」CAS:327178-94-9|12-Dipalmitoyl-sn-glycero-3-PS-d62 sodium
作者：德尔塔生物 日期：2025-06-13
生物活性：12-Dipalmitoyl-sn-glycero-3-PS-d62 (sodium) is deuterium labeled 12-Dipalmitoyl-sn-glycero-3-PS.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[2].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：820.33Formula：C38H11D62NNaO10PCAS 号：327178-94-9非标记 CAS：145849-32-7性状：固体颜色：White to off-white运输条件：Room temperature in continental US; may vary elsewhere.储存方式：-20°C, sealed storage, away from moisture*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)纯度 & 产品资料纯度： ≥99.0%参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」CAS:2749985-37-1|trans-Hydroxy Glimepiride-d4
作者：德尔塔生物 日期：2025-06-13
生物活性：trans-Hydroxy Glimepiride-d4 is deuterium labeled trans-Hydroxy Glimepiride.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：510.64Formula：C24H30D4N4O6SCAS 号：2749985-37-1非标记 CAS：600177-94-4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (516 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1126745-58-1|Ziprasidone-d8
作者：德尔塔生物 日期：2025-06-13
生物活性：Ziprasidone-d88 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.分子量：420.98Formula：C21H13D8ClN4OSCAS 号：1126745-58-1非标记 CAS：146939-27-7性状：固体颜色：Light yellow to khaki中文名称：齐拉西酮-d8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month纯度 & 产品资料Data Sheet (495 KB)产品使用指南 (1538 KB)
-
「同位素标记抑制剂」CAS:136765-35-0|Haloperidol-d4-1
作者：德尔塔生物 日期：2025-06-13
生物活性：Haloperidol-d4-1 is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.IC50 & Target：D2 Receptor分子量：379.89Formula：C21H19D4ClFNO2CAS 号：136765-35-0非标记 CAS：52-86-8性状：固体颜色：White to off-white中文名称：氟哌啶醇 d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 yearsIn solvent：-80°C：6 months，-20°C：1 month
-
「同位素标记抑制剂」CAS:2749974-94-3|W-19-d4 hydrochloride
作者：德尔塔生物 日期：2025-06-13
生物活性：W-19-d4 (hydrochloride) is the deuterium labeled W-19 hydrochloride[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：432.40Formula：C19H19D4Cl2N3O2SCAS 号：2749974-94-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (522 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1217719-21-5|cis-Dihydro Tetrabenazine-d7
作者：德尔塔生物 日期：2025-06-13
生物活性：cis-Dihydro Tetrabenazine-d7 is the deuterium labeled cis-Dihydro Tetrabenazine[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：326.48Formula：C19H22D7NO3CAS 号：1217719-21-5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」CAS:2642083-16-5|(Rac)-Paclobutrazol-15N3
作者：德尔塔生物 日期：2025-06-13
生物活性：(Rac)-Paclobutrazol-15N3 is the 15N-labeled Rac-Paclobutrazol[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(Rac)-Paclobutrazol-15N3 相关抗体:SDHA Antibody分子量：296.77Formula：C15H20Cl15N3OCAS 号：2642083-16-5非标记 CAS：76738-62-0中文名称：(Rac)-多效唑-15N3；(Rac)-氯丁唑-15N3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1261394-10-8|Cyclobenzaprine-13C,d3 hydrochloride
作者：德尔塔生物 日期：2025-06-13
生物活性：Cyclobenzaprine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Cyclobenzaprine (hydrochloride).体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[60].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Cyclobenzaprine-13C,d3 hydrochloride 相关抗体:MTNR1A Antibody分子量：315.86Formula：C1913CH19D3ClNCAS 号：1261394-10-8非标记 CAS：6202-23-9中文名称：阿米替林EP杂质B-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (527 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief][2]. Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311(1): p. 29-35. [Content Brief][3]. Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol, 2003. 458(1-2): p. 91-9. [Content Brief]
-
「同位素标记抑制剂」CAS:2747918-20-1|Lercanidipine-13C,d3-1 hydrochloride
作者：德尔塔生物 日期：2025-06-13
生物活性：Lercanidipine-13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[1][2][3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Lercanidipine-13C,d3-1 hydrochloride 相关抗体:Annexin VI AntibodyCalbindin AntibodyCalreticulin AntibodyCardiac Troponin I/TNNC1 AntibodySCGN Antibody (YA1167)RAMP1 Antibody (YA1818)Annexin V Antibody (YA1829)Striatin 4 Antibody (YA2088)Fibulin 5 Antibody (YA2448)RASGRP1 Antibody (YA2546)Fibulin 1 Antibody (YA2831)EFEMP1 Antibody (YA2883)CRCP Antibody (YA3350)Annexin VII Antibody (YA1138)Parvalbumin Antibody (YA1249)Annexin IV Antibody (YA1921)SERCA2 ATPase Antibody (YA1931)Stromal Interaction Molecule 1 Antibody (YA2092)SERCA1 ATPase Antibody (YA2157)TrpV5 Antibody (YA2284)NCX1 Antibody (YA2331)Scramblase 1 Antibody (YA2419)CAB39 Antibody (YA2761)CUG BP1 Antibody (YA2806)C10orf63 Antibody (YA2894)ITPK1 Antibody (YA3125)ORAI3 Antibody (YA3128)ORAI1 Antibody (YA3157)CREB Regulated Transcription Coactivator 2 Antibody (YA3279)分子量：652.20Formula
-
「同位素标记抑制剂」CAS:2517756-06-6|Lamotrigine-13C,d3
作者：德尔塔生物 日期：2025-06-13
生物活性：Lamotrigine-13C,d3 is the 13C- and deuterium labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[84].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Lamotrigine-13C,d3 相关抗体:xCT Antibody (YA006)xCT Antibody (YA652)Alpha-ENaC AntibodyCRMP2 Antibody (YA3370)SLC12A1 Antibody (YA1403)CRMP1 Antibody (YA1941)CRMP5 Antibody (YA2497)CRMP3 Antibody (YA2563)CRMP4 Antibody (YA2777)分子量：260.10Formula：C813CH4D3Cl2N5CAS 号：2517756-06-6非标记 CAS：84057-84-1中文名称：拉莫三嗪-13C,d3；那蒙特金-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (536 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief][2]. M J Leach, et al. Pharmacological studies on lamotrigine,
-
「同位素标记抑制剂」CAS:2744683-81-4|Famotidine-13C,d3
作者：德尔塔生物 日期：2025-06-13
生物活性：Famotidine-13C,d3 is the 13C- and deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.IC50 & Target：H2 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[63].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Famotidine-13C,d3 相关抗体:ADGRE1 (F4/80) Antibody (YA002)ADGRE1 (F4/80) Antibody (YA920)分子量：341.46Formula：C713CH12D3N7O2S3CAS 号：2744683-81-4非标记 CAS：76824-35-6中文名称：法莫替丁-13C,d3；法莫丁-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (524 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief][2]. Inan, A., et al., Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo), 2009. 64(6): p. 567-70. [Content Brief][3]. Miyata, K., et al., Studies on the mechanism for the gastric mucosal protection by famotidine in rats. Jpn J Pharmacol, 1991. 55(2): p. 211-22. [Con
咨询热线
18133906270
德尔塔官方微信